Celltrion and Amgen Reach Settlement in Prolia® / Xgeva® Biosimilar Litigation | Venable LLP
On January 24, 2025, Amgen announced it had reached a settlement with Celltrion in Case No. 1:24-cv-06497 (D.N.J.) related to Celltrion’s proposed biosimilar of Prolia® / Xgeva® (denosumab), CT-P41. The lawsuit involved allegations of infringement of 29 of Amgen’s patents (previously reported Amgen Files BPCIA Lawsuit Against Celltrion’s Proposed Prolia® / Xgeva® (Denosumab) Biosimilar CT-P41). […]